The Reproducibility of Microvascular Flow Imaging in Fibroids and Its Correlation With 2D and 3D Power Doppler Outcomes
NCT ID: NCT05643339
Last Updated: 2022-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2021-02-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Uterine Artery Occlusion for Fibroid Related Bleeding
NCT00496067
Measuring Endometrial Blood Flow Using Laser Doppler: Acceptability & Reproducibility
NCT04906551
Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids
NCT00746031
New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs
NCT06373822
Uterine Artery Embolization for Symptomatic Fibroids
NCT00354471
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
microvascular flow imaging
microvascular flow imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diameter between 1,5 and 12 cm
* fibroid easily recognizable on ultrasound
Exclusion Criteria
* pregnancy
* uterine or cervical malignancy
* adenomyosis.
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marjolein Spiering
Investigator Reseach Office Womens Child Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Judith Huirne, Prof.
Role: PRINCIPAL_INVESTIGATOR
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Amsterdam UMC
Amsterdam, North Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017/494 and W20_274
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.